- 0.75 credits
- 25 a la carte
- ANCC, AMA
This activity is part of a 14-course series designed to equip licensed practitioners from medical, nursing, and related disciplines with a multidisciplinary approach to managing patients with psoriasis.
13. Biosmilars: Where Are We Now?
Biosimilar medications are "highly similar" to an already FDA-approved biological product. Several biosimilars have already been approved in the US for the treatment of psoriasis, with more sure to follow in the near future. The FDA is responsible for and has a process for ensuring the safety and efficacy of biosimilars.
After completing this activity, participants will able to:
The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:
|Name of Faculty||Reported Financial Relationship|
|Paul Yamauchi, MD, PhD||
Consultant/Speaker/Principlal Investigator: AbbVie, Amgen, Celgene Corporation, Dermira, Galderma USAJanssen-Orth Inc., LEO Pharma, US, Lilly ICOS LLC, Medimmune, Menlo Therapeutics, Novartis Pharmaceuticals Corp., Ortho Dermatologics, Pfizer Inc., Regneron, Sun Pharmaceutical Industries Ltd.
Advisory Board: Amgen, Dermira, Lilly ICOS LLC
This activity is jointly provided by SynAptiv and LearnHealth Inc.
Questions about CE accreditation or CE certificates related to this course, please contact us via email at email@example.com. For all other questions, please contact firstname.lastname@example.org.
Copyright © 2018 LearnHealth Inc. All rights reserved. This material may not be reproduced, displayed, modified or distributed without the express prior written permission of the copyright holder.